OClawVPS.com
DTx Pharma
Edit

DTx Pharma

http://www.dtxpharma.com/
Last activity: 19.06.2024
Active
Categories: BioTechBodyDeliveryDevelopmentDrugITMedtechPlatformTechnology
At DTx, we are a group of flexible, innovative thinkers who are determined to solve one of the biggest challenges limiting the development of genetic medicines.
Mentions
27
Employees: 11-50
Total raised: $103M
Founded date: 2017

Investors 6

Funding Rounds 2

DateSeriesAmountInvestors
17.03.2021Series B$100M-
14.05.2019-$3M-

Mentions in press and media 27

DateTitleDescription
19.06.2024CMT Research Foundation Invests in ReviR Therapeutics Research to Pioneer Small Molecule Therapeutics for CMT1AATLANTA, June 19, 2024 /PRNewswire/ -- The CMT Research Foundation, a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT)*, has formed a strategic partnership with ReviR Therapeutics to advance...
28.07.2023Latest Updates of 7 Viva's Portfolio CompaniesHONG KONG, July 28, 2023 /PRNewswire/ -- In the face of ever-changing circumstances, technological innovation remains the eternal driving force behind the long-term growth of biopharmaceutical companies. It continuously breathes life into t...
18.07.2023Novartis Acquires DTx Pharma, for Approx. USD1 BillionNovartis acquired DTx Pharma, a San Diego, CA-based biotechnology company, for approx. $1 Billion. Novartis will make an upfront payment of $500M and additional payments of up to $500M upon completion of pre-specified milestones. The acquis...
18.07.2023Viva Biotech's Portfolio Company DTx Pharma Reached the Acquisition Agreement with NovartisDTx Pharma's Fatty Acid Ligand Conjugated Oligonucleotide (FALCON™) platform facilitates extra-hepatic delivery of siRNA therapeutics Acquisition includes DTx-1252 with the potential to deliver a transformative medicine to Charcot-Marie-Too...
04.06.2022From Stem Cells to Biosensors: 3 Trends To Watch at This Year’s First Look Startup ShowcaseSome 15-odd years ago, the Alliance for SoCal Innovation put on a workshop for academics looking to wade into the world of commercialized technology. Fast forward to 2022 and the Alliance is gearing up for the latest edition of its annual F...
07.04.2021DTx Pharma to Participate in the 2021 Needham Virtual Healthcare Conference
17.03.2021DTx Pharma Raises $100 Million RoundPhoto courtesy of DTx Pharma. In May 2020, the biotech expanded its footprint into a new 14,000 square foot lab and office space in Sorrento Valley. San Diego-based DTx Pharma, a biotechnology company creating novel RNA-based therapeutics t...
05.03.2021DTx Pharma Closes $100M Series B FinancingDTx Pharma, Inc., a San Diego, CA-based biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, completed a $100m Series B financing. The round was led by RA Capital Management with participation...
04.03.2021DTx soars to $100 million Series B to advance falcon™PlatformWe were first introduced to DTx founder and CEO Artie Suckow in June 2017. DTx formed to unlock RNA therapeutics' promise and overcome challenges inherent in delivering this therapeutic class to an array of different tissues and cell types....
01.03.2021DTx Pharma : Completes $100M Series B Financing to Advance its FALCON™ Platform and Pipeline of RNA TherapeuticsSAN DIEGO, March 1, 2021 /PRNewswire/ -- DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today the completion of a $100 million Series B...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In